Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products, a growing area that requires specialist knowledge and expertise. The group has a global customer base which includes the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups.
The term “Abzena inside” is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners and include Composite Human Antibodies™ and ThioBridge™ antibody drug conjugates. Abzena has the potential to earn future licence fees, milestone payments and/or royalties on “Abzena inside” products.
Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):
- Immunogenicity assessment, protein engineering to create humanised antibodies and deimmunised therapeutic proteins, and cell line development for manufacture.
- Contract process development and manufacture of biopharmaceuticals, including monoclonal antibodies, recombinant proteins, vaccines, gene therapy and cell therapy products for preclinical and clinical studies.
- Proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimising the therapeutic properties of biopharmaceuticals.
- Contract chemistry and bioconjugation business focused on ADCs and is establishing the capability to manufacture ADCs to GMP standards.
A successful IPO of Abzena was achieved on 24 August 2014, which you can read more about here. Mercia successfully exited from Abzena (a joint University of Warwick and Imperial College spinout) in 2017. This is the second profitable cash exit which Mercia has achieved during its short time on AIM; an achievement which demonstrates the significant potential held within the portfolio.